TIDMREDX

RNS Number : 6549S

Redx Pharma plc

17 November 2021

REDX PHARMA PLC

("Redx" or the "Company")

Redx to Present at Jefferies London Healthcare Conference

Alderley Park, UK, 17 November 2021 - Redx Pharma (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announces that Lisa Anson, Chief Executive Officer, will be presenting at the Jefferies London Healthcare Conference today, Wednesday 17 November at 08:40am GMT.

The webcast can be accessed here: https://wsw.com/webcast/jeff201/redx.l/2066166

 
For further information, please contact: 
 
Redx Pharma Plc                              T: +44 (0)1625 469 
                                              918 
 UK Headquarters 
 Lisa Anson, Chief Executive Officer 
Karl Hård, Head of Investor Relations 
 k.hard@redxpharma.com 
 
  US Office 
  Peter Collum, Chief Financial Officer 
 
SPARK Advisory Partners (Nominated Adviser)   T: +44 (0)203 368 
                                               3550 
Matt Davis/ Adam Dawes 
 
WG Partners LLP (Joint Broker)               T: +44 (0)203 705 
                                              9330 
Claes Spång/ David Wilson 
 
Panmure Gordon (UK) Limited (Joint Broker)   T: +44 (0)207 886 
                                              2500 
Rupert Dearden/ Freddy Crossley/ Emma Earl 
 
FTI Consulting                               T: +44 (0)203 727 
                                              1000 
Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by the two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by the four strategic transactions from which has emerged the most advanced product candidate pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology. In addition, Redx has forged pre-clinical collaborations with AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUBUNRASUAARA

(END) Dow Jones Newswires

November 17, 2021 02:00 ET (07:00 GMT)

Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Redx Pharma.
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Redx Pharma.